Precision Biosciences (DTIL) Amortization of Deferred Charges (2019 - 2026)

Precision Biosciences (DTIL) has 8 years of Amortization of Deferred Charges data on file, last reported at $341000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 10.0% year-over-year to $341000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 9.76% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 9.55% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $341000.0, up from $333000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for DTIL reached as high as $420000.0 in Q2 2023 and fell as low as $277000.0 in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $320176.5 across 5 years, with a median of $310000.0 in 2025.
• Across the five-year window, Amortization of Deferred Charges soared 41.41% in 2023 and plunged 30.95% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $315000.0 in 2022, then declined by 12.06% to $277000.0 in 2023, then grew by 9.39% to $303000.0 in 2024, then gained by 9.9% to $333000.0 in 2025, then increased by 2.4% to $341000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $341000.0 in Q1 2026, $333000.0 in Q4 2025, and $324000.0 in Q3 2025.